A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).Jann N. Sarkaria, Evanthia Galanis, Kurt A. Jaeckle et al.|Journal of Clinical Oncology|2024Cited by 3